- CITATIONS: 1
|Application ||WB, IHC-P, E|
|Other Accession||P27881, Q1W674, O08528|
|Predicted||Mouse, Pig, Rat|
|Calculated MW||102380 Da|
|Antigen Region||91-121 aa|
|Other Names||Hexokinase-2, Hexokinase type II, HK II, Muscle form hexokinase, HK2|
|Target/Specificity||This HK2 (Hexokinase II) antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 91-121 amino acids from the N-terminal region of human HK2 (Hexokinase II).|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||HK2 (Hexokinase II) Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Cellular Location||Mitochondrion outer membrane. Note=Its hydrophobic N-terminal sequence may be involved in membrane binding.|
|Tissue Location||Predominant hexokinase isozyme expressed in insulin-responsive tissues such as skeletal muscle|
Provided below are standard protocols that you may find useful for product applications.
In vertebrates there are four major glucose-phosphorylating isoenzymes, designated hexokinase I, II, III, and IV. Hexokinase is an allosteric enzyme inhibited by its product GLC-6-P. Hexokinase activity is involved in the first step in several metabolic pathways. HK3 is bound to the outer mitochondrial membrane. Its hydrophobic N-terminal sequence may be involved in membrane bindng. It is the predominant hexokinase isozyme expressed in insuline-responsive tissues such as skeletal muscle. The N- and C-terminal halves of this hexokinase show extensive sequence similarity to each other. The catalytic activity is associated with the C-terminus while regulatory function is associated wiht the N-terminus. Although found in NIDDM patients, genetic variations of HK2 do not contribute to the disease.
Lehto, M., et al., Diabetologia 38(12):1466-1474 (1995).
Vidal-Puig, A., et al., Diabetes 44(3):340-346 (1995).
Laakso, M., et al., Diabetes 44(3):330-334 (1995).
Echwald, S.M., et al., Diabetes 44(3):347-353 (1995).
Shinohara, Y., et al., Cancer Lett. 82(1):27-32 (1994).
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.